Immutep Insider Holdings Show Mixed Signals Amid IMP761 Trial & Performance-Right Grants
Insider activity shows Immutep’s CEO holds 4 m shares while awaiting key milestones like IMP761 trial results and a Q3 2026 root‑cause report—patience amid upside potential.
4 minutes to read